Physician profile
Alexandre Monteiro
NPI 1174122147
$3,183.71
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $711 · 2023: $1,167 · 2024: $713 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.49 | 2022-2025 | |
| Janssen Biotech, INC. | $393.58 | 2021-2024 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.86 | 2021-2024 | Xifaxan |
| Daiichi Sankyo INC. | $254.16 | 2021-2024 | Injectafer |
| Redhill Biopharma INC. | $223.25 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $206.95 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $150.42 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $140.43 | 2022-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $98.99 | 2022-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $84.14 | 2022-2024 | Dupixent |
| Genzyme Corporation | $77.28 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $46.35 | 2024 | |
| Exact Sciences Corporation | $36.69 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $32.78 | 2021 | |
| Galderma Laboratories, L.P. | $29.91 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $27.41 | 2023 | Sutab |
| Celltrion USA INC. | $25.86 | 2025 | Vegzelma |
| Merz North America, INC. | $23.24 | 2025 | |
| Gilead Sciences, INC. | $22.24 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.92 | 2022 | |
| Medtronic, INC. | $15.76 | 2024 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandre Monteiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.